Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Misra

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
JAMA Cardiology|June 16, 2021
The First StepPriya Misra
Academic Pediatrics|January 25, 2022
Everything We CanPriya Misra
Experimental Hematology & Oncology|September 12, 2018
Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapyKalpna Desai, Priya Misra, Sanyukta Kher, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar PegfilgrastimKalpna Desai, Tina Catalano, Gurinder Rai, et al.
Pediatrics|February 3, 2023
Increasing Utilization of the Preparticipation Physical EvaluationChrista Miliaresis, Priya Misra, Deborah Friedman, et al.
Scientific Reports|January 11, 2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingChristian Schoergenhofer, Michael Schwameis, Christa Firbas, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
JAMA Cardiology|June 16, 2021
The First StepPriya Misra
Academic Pediatrics|January 25, 2022
Everything We CanPriya Misra
Experimental Hematology & Oncology|September 12, 2018
Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapyKalpna Desai, Priya Misra, Sanyukta Kher, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar PegfilgrastimKalpna Desai, Tina Catalano, Gurinder Rai, et al.
Pediatrics|February 3, 2023
Increasing Utilization of the Preparticipation Physical EvaluationChrista Miliaresis, Priya Misra, Deborah Friedman, et al.
Scientific Reports|January 11, 2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingChristian Schoergenhofer, Michael Schwameis, Christa Firbas, et al.
Pageof 1